BioLineRx (BLRX) Stock Price, News & Analysis

Company Overview

BioLineRx (NASDAQ: BLRX) is a clinical-stage biopharmaceutical company that discovers and develops novel small-molecule therapies to address unmet medical needs. The company focuses on identifying promising drug candidates through licensing and collaboration agreements with academic institutions and biotech innovators, then advancing these candidates through preclinical and clinical development stages. BioLineRx’s pipeline spans oncology, immunology and inflammatory diseases, central nervous system disorders and pain management.

Among its clinical programs, BioLineRx is advancing targeted cancer therapies designed to improve outcomes for patients with difficult-to-treat tumors. In immunology and inflammatory diseases, the company is developing novel agents that modulate key biological pathways to reduce disease activity with minimal side effects. BioLineRx also explores treatments for neuropathic pain and other central nervous system conditions, seeking to offer new therapeutic options where few effective treatments exist.

Headquartered in Modi’in, Israel, BioLineRx maintains strategic partnerships and licensing arrangements across North America, Europe and Asia to support its global development efforts. By leveraging a business model that combines in-licensing, co-development and out-licensing of assets, the company aims to maximize the value of its pipeline while managing development risk. BioLineRx collaborates with contract research organizations and clinical centers worldwide to conduct multi-site trials and accelerate the advancement of its drug candidates.

Key Stats

• Today's Range: $4.00 to $4.14
• 50-Day Range: $3.55 to $4.24
• 52-Week Range: $2.30 to $22.60
• Volume: 37,813 shs
• Average Volume: 310,690 shs
• Market Capitalization: $17.78 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $26.00
• Consensus Rating: Moderate Buy

BioLineRx Stock Analysis - MarketRank™

BioLineRx scored higher than 51% of companies evaluated by MarketBeat, and ranked 454th out of 942 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

BioLineRx has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

BioLineRx has a consensus price target of $26.00, representing about 536.5% upside from its current price of $4.09.

Amount of Analyst Coverage

BioLineRx has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for BioLineRx are expected to grow in the coming year, from ($5.80) to ($5.60) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of BioLineRx is -0.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of BioLineRx is -0.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

BioLineRx has a P/B Ratio of 1.01. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.03% of the float of BioLineRx has been sold short.

Short Interest Ratio / Days to Cover

BioLineRx has a short interest ratio ("days to cover") of 4.7.

Change versus previous month

Short interest in BioLineRx has recently decreased by 5.79%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BioLineRx does not currently pay a dividend.

Dividend Growth

BioLineRx does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.03% of the float of BioLineRx has been sold short.

Short Interest Ratio / Days to Cover

BioLineRx has a short interest ratio ("days to cover") of 4.7.

Change versus previous month

Short interest in BioLineRx has recently decreased by 5.79%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.26

News Sentiment

BioLineRx has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for BioLineRx this week, compared to 1 article on an average week.

Search Interest

2 people have searched for BLRX on MarketBeat in the last 30 days.

MarketBeat Follows

6 people have added BioLineRx to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, BioLineRx insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.10% of the stock of BioLineRx is held by insiders.

Percentage Held by Institutions

Only 1.56% of the stock of BioLineRx is held by institutions.

BLRX Stock Analysis - Frequently Asked Questions

How have BLRX shares performed this year?

BioLineRx's stock was trading at $8.56 at the start of the year. Since then, BLRX stock has decreased by 52.3% and is now trading at $4.0850.

How were BioLineRx's earnings last quarter?

BioLineRx Ltd. (NASDAQ:BLRX) issued its quarterly earnings data on Thursday, August, 14th. The biotechnology company reported ($1.00) earnings per share for the quarter, missing the consensus estimate of ($0.35) by $0.65. The biotechnology company earned $0.30 million during the quarter, compared to analyst estimates of $0.66 million. BioLineRx had a negative net margin of 45.34% and a negative trailing twelve-month return on equity of 49.74%.
Read the conference call transcript.

When did BioLineRx's stock split?

BioLineRx's stock reverse split on the morning of Thursday, January 30th 2025.The 1-40 reverse split was announced on Friday, January 17th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, January 29th 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

How do I buy shares of BioLineRx?

Shares of BLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of BioLineRx own?

Based on aggregate information from My MarketBeat watchlists, some other companies that BioLineRx investors own include Savara (SVRA), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Meta Platforms (META), Brainstorm Cell Therapeutics (BCLI) and Tesla (TSLA).

Company Calendar

• Last Earnings: 8/14/2025
• Today: 10/06/2025
• Next Earnings (Estimated): 11/24/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BLRX
• CIK: 1498403
• Web: www.biolinerx.com
• Phone: (728) 642-9100
• Fax: 972-8642-9101
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Price Target for BioLineRx: $26.00
• High Price Target: $26.00
• Low Price Target: $26.00
• Potential Upside/Downside: +536.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($8.80)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$9.22 million
• Net Margins: -45.34%
• Pretax Margin: -45.34%
• Return on Equity: -49.74%
• Return on Assets: -17.54%

Debt

• Debt-to-Equity Ratio: 0.33
• Current Ratio: 2.06
• Quick Ratio: 1.87

Sales & Book Value

• Annual Sales: $17.25 million
• Price / Sales: 1.01
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.04 per share
• Price / Book: 1.01

Miscellaneous

• Outstanding Shares: 4,263,000
• Free Float: 4,216,000
• Market Cap: $17.41 million
• Optionable: Optionable
• Beta: 1.25